The New Eugenics
By Michael Dorsey,
World Watch
| 06. 30. 2002
On a not too distant horizon, advances in human biotechnology
may enable us to engineer the specific genetic makeup of our
children. Only a few months ago, the headlinemaking Italian
doctor Severino Antinori claimed to have implanted cloned embryos
in several women. We are already at the stage where we can selectively
terminate our offspring if certain genetic criteria are not
met. Soon it may be possible to discern, and ultimately select
for or against, individual traits in our children.
It is at this juncture that the promise of biotechnology runs
head-on into the history and the horrors of eugenics— the
quest for biological “improvement” through reproductive
control.
At the start of the 20th century, British scientist Francis
Galton coined the term eugenics, from the Greek eugenes, for
“well-born.” He later distinguished two major kinds
of eugenics, positive and negative. “Positive eugenics”
was preferential breeding of socalled “superior individuals”
in order to improve the genetic stock of the human race. “Negative
eugenics” meant discouraging or legally prohibiting reproduction
by individuals thought to have “inferior” genes and
was to be “achieved...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...